长春碱
细胞凋亡
紫杉醇
流式细胞术
赫拉
有丝分裂
材料科学
细胞仪
细胞
癌细胞
程序性细胞死亡
化学
生物物理学
细胞生物学
生物
癌症
免疫学
化疗
生物化学
遗传学
作者
Xinlong Yang,Ziheng Liang,Yuan Luo,Xueyuan Yuan,Yao Cai,Duli Yu,Xiaoxing Xing
出处
期刊:Lab on a Chip
[The Royal Society of Chemistry]
日期:2023-01-01
卷期号:23 (22): 4848-4859
被引量:7
摘要
Chemotherapeutic drugs such as paclitaxel and vinblastine interact with microtubules and thus induce complex cell states of mitosis arrest at the G2/M phase followed by apoptosis dependent on drug exposure time and concentration. Microfluidic impedance cytometry (MIC), as a label-free and high-throughput technology for single-cell analysis, has been applied for viability assay of cancer cells post drug exposure at fixed time and dosage, yet verification of this technique for varied tumor cell states after anticancer drug treatment remains a challenge. Here we present a novel MIC device and for the first time perform impedance cytometry on carcinoma cells exhibiting progressive states of G2/M arrest followed by apoptosis related to drug concentration and exposure time, after treatments with paclitaxel and vinblastine, respectively. Our results from impedance cytometry reveal increased amplitude and negative phase shift at low frequency as well as higher opacity for HeLa cells under G2/M mitotic arrest compared to untreated cells. The cells under apoptosis, on the other hand, exhibit opposite changes in these electrical parameters. Therefore, the impedance features differentiate the HeLa cells under progressive states post anticancer drug treatment. We also demonstrate that vinblastine poses a more potent drug effect than paclitaxel especially at low concentrations. Our device is fabricated using a unique sacrificial layer-free soft lithography process as compared to the existing MIC device, which gives rise to readily aligned parallel microelectrodes made of silver-PDMS embedded in PDMS channel sidewalls with one molding step. Our results uncover the potential of the MIC device, with a fairly simple and low-cost fabrication process, for cellular state screening in anticancer drug therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI